The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
Projects selected for advancement will move forward through the Harvard Office of Technology Development’s processes for sponsored research agreements
The acquisition combines Firstsource’s market-leading AI and automation capabilities with TeleMedik’s operational footprint in Puerto Rico
AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing
Subscribe To Our Newsletter & Stay Updated